Comparison of the effects of hydralazine on tumor and normal tissue blood perfusion by MRI.
Int J Radiat Oncol Biol Phys 1994;
29:473-9. [PMID:
8005802 DOI:
10.1016/0360-3016(94)90441-3]
[Citation(s) in RCA: 16] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
PURPOSE
The differential effects on blood perfusion of the vasodilator hydralazine (HYD) between tumor and normal muscle have been measured using the dynamic enhanced-magnetic resonance imaging (DE-MRI) technique.
METHODS AND MATERIALS
DE-MRI is a noninvasive method of determining blood perfusion in tumors and normal tissues using the MR contrast agent Gd-DTPA. Hydralazine is currently being used in an attempt to increase tumor response to bioreductive agents and to hyperthermia.
RESULTS
We show that a dose of 1.2 mg/kg HYD causes an increase in tumor perfusion while doses > or = 2.5 mg/kg cause a decrease in tumor perfusion. The latter was accompanied by a dose-dependent increase in normal muscle perfusion consistent with the "steal effect."
CONCLUSION
This study demonstrates the sensitivity of the DE-MRI technique and its capability of providing estimates of blood perfusion in normal and tumor tissue as well as in smaller regions of a solid tumor. Such features would make it clinically useful in the study of tumor response to radiation therapy and chemotherapy in patients.
Collapse